ASH 2024
American Society of Hematology Annual Meeting
Interviews and expert commentary from ASH 2024 — study authors and key opinion leaders discuss the findings and their clinical implications.
Jennifer A. Woyach MD, ASH 2024: The Non-Covalent Bruton’s Tyrosine Kinase-Inhibitor Pirtobrutinib is As Effective, While Less Toxic, In Relapsed/Refractory Chronic Lymphocytic Leukemia
Dr. Jennifer A. Woyach discusses promising phase III study findings at ASH 2025, revealing that the non-covalent BTK inhibitor pirtobrutinib is as effective as ibrutinib, while demonstrating less toxicity, in patients with relapsed/refractory and treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma. This first randomized head-to-head comparison shows pirtobrutinib met its primary endpoint of non-inferiority for overall response rate.
Jenny Paredes PhD, Duarte, CA: Increased Dietary Fiber Brings Longer Survival and Less GVHD After Allogeneic Stem Cell Transplantation
The microbiome is emerging as a powerful ally to cancer doctors to harness in tandem with curative therapies, especially with allogeneic stem cell transplantation.
Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia
Audio Journal of Oncology Podcast December, 2024: Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia Hua Zhang MD PhD (Chief Scientific Officer with S